Close Menu

Bioinformatics Billions

Premium

In two short months the number of publicly-traded bioinformatics companies has jumped from zero to four. Herewith, a quick take on valuations to date.

Lion and Compugen debuted in August, Genomica in September, and InforMax in October. And at press time their combined market capitalization was an impressive $2.86 billion — not bad for companies with aggregate annual revenues of less than $30 million. As a group the share price/revenue ratio is about 105.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.